Key points are not available for this paper at this time.
Sarilumab showed significant efficacy in achieving sustained remission and reducing the cumulative glucocorticoid dose in patients with a relapse of polymyalgia rheumatica during glucocorticoid tapering. (Funded by Sanofi and Regeneron Pharmaceuticals; SAPHYR ClinicalTrials.gov number, NCT03600818.).
Building similarity graph...
Analyzing shared references across papers
Loading...
Robert Spiera
Hospital for Special Surgery
Sebastian Unizony
Harvard University
Kenneth J. Warrington
Mayo Clinic
New England Journal of Medicine
Harvard University
Cornell University
Massachusetts General Hospital
Building similarity graph...
Analyzing shared references across papers
Loading...
Spiera et al. (Wed,) studied this question.
synapsesocial.com/papers/69daa3232d871caad68358b8 — DOI: https://doi.org/10.1056/nejmoa2303452